OBJECTIVE: We aimed to investigate significance of smoking regarding pathologic and biochemical outcomes following radical prostatectomy (RP). MATERIALS AND METHODS: We reviewed data of 1,165 patients who underwent RP without any neoadjuvant or adjuvant therapy at our institution. Patients were categorized into two groups for our analysis: smoking (current smoker at admission for surgery) and nonsmoking (never smoked or former smokers) group. Association of smoking status with adverse pathologic features and biochemical recurrence-free survival were analyzed according to patients' body mass index (BMI) as well as in total patients. RESULTS: In multivariate analyses, smoking was not found to be significantly associated with various adverse pathologic features and biochemical recurrence-free survival among total patients (all P > 0.05). However, when only the patients with BMI ≥ 25 kg/m(2) were analyzed, smoking at RP was observed to be an independent preoperative predictor of high (≥ 8) pathologic Gleason score (P = 0.025) and biochemical recurrence-free survival (P = 0.016) in multivariate analyses. CONCLUSIONS: Although smoking was not observed to be significantly associated with worse pathologic and biochemical outcome among overall patients who underwent RP, smoking was found to be a significant preoperative predictor of more aggressive disease and worse biochemical outcome among those with relatively higher BMI.
OBJECTIVE: We aimed to investigate significance of smoking regarding pathologic and biochemical outcomes following radical prostatectomy (RP). MATERIALS AND METHODS: We reviewed data of 1,165 patients who underwent RP without any neoadjuvant or adjuvant therapy at our institution. Patients were categorized into two groups for our analysis: smoking (current smoker at admission for surgery) and nonsmoking (never smoked or former smokers) group. Association of smoking status with adverse pathologic features and biochemical recurrence-free survival were analyzed according to patients' body mass index (BMI) as well as in total patients. RESULTS: In multivariate analyses, smoking was not found to be significantly associated with various adverse pathologic features and biochemical recurrence-free survival among total patients (all P > 0.05). However, when only the patients with BMI ≥ 25 kg/m(2) were analyzed, smoking at RP was observed to be an independent preoperative predictor of high (≥ 8) pathologic Gleason score (P = 0.025) and biochemical recurrence-free survival (P = 0.016) in multivariate analyses. CONCLUSIONS: Although smoking was not observed to be significantly associated with worse pathologic and biochemical outcome among overall patients who underwent RP, smoking was found to be a significant preoperative predictor of more aggressive disease and worse biochemical outcome among those with relatively higher BMI.
Authors: E Giovannucci; E B Rimm; A Ascherio; G A Colditz; D Spiegelman; M J Stampfer; W C Willett Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-04 Impact factor: 4.254
Authors: Lora A Plaskon; David F Penson; Thomas L Vaughan; Janet L Stanford Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-07 Impact factor: 4.254
Authors: Zhihong Gong; Ilir Agalliu; Daniel W Lin; Janet L Stanford; Alan R Kristal Journal: Cancer Causes Control Date: 2007-09-30 Impact factor: 2.506
Authors: Stephen J Freedland; William J Aronson; Christopher J Kane; Joseph C Presti; Christopher L Amling; David Elashoff; Martha K Terris Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544
Authors: June M Chan; Stacey A Kenfield; Rebecca E Graff; Crystal S Langlais; Erin L Van Blarigan; Claire H Pernar; Meir J Stampfer; Edward L Giovannucci; Lorelei A Mucci Journal: Br J Cancer Date: 2022-08-26 Impact factor: 9.075
Authors: Crystal S Langlais; Rebecca E Graff; Erin L Van Blarigan; Nynikka R Palmer; Samuel L Washington; June M Chan; Stacey A Kenfield Journal: Curr Oncol Rep Date: 2021-03-10 Impact factor: 5.075